Boehringer-Ingelheim
Burning Rock, Boehringer Ingelheim Ink Master Service Agreement for Oncology Companion Diagnostics
The companies will focus initially on Boehringer Ingelheim's MDM2-p53 antagonist, brigimadlin, now being studied in a new Phase II trial in China.
Thermo Fisher Scientific, Boehringer Ingelheim Partner on Companion Dx for Lung Cancer
The firms will develop multiple NGS-based companion diagnostic tests based on the Oncomine Dx Express Test and Oncomine Dx Target Test.
Novartis Joins Industry Fray in Filing Medicare Price Setting Lawsuit; Alleges Free Speech Violation
The drugmaker is suing the US government claiming that the IRA stymies innovation and compels Novartis to say it engaged in negotiations over CMS-set prices.
Although traditional biomarker-targeted therapies haven't benefitted patients with this aggressive form of lung cancer, pharma firms and researchers are trying out new biomarkers and ctDNA monitoring.
Oxford BioTherapeutics, Boehringer Ingelheim Extend Drug Discovery Collaboration
The firms have previously advanced two programs identified by Oxford's platform into Phase I clinical development.